-+ 0.00%
-+ 0.00%
-+ 0.00%
Teva Pharmaceutical Industries CEO Says Just-Launched Schizophrenia Drug Weltruza Won't See Significant Revenue Until Second Half Of 2027, In Good Position For 2028; Despite Growth In Branded Drugs, Generics To Continue To Grow And Be Profitable Due To Biosimilars Pipeline; Co. Aims To Grow In 2027 Despite U.S. Inflation Reduction Act Impact On Its Austedo Drug
Share
Listen to the news

-Conference Call. 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending